| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BWS; WBS; p57; BWCR; KIP2; p57Kip2 |
| Entrez GeneID | 1028 |
| clone | 8G5D5 |
| WB Predicted band size | 32.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CDKN1C expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CDKN1C抗体的3篇参考文献示例(注：文献为虚构示例，仅用于格式参考)：
1. **文献名称**: *"CDKN1C/p57Kip2 in Beckwith-Wiedemann Syndrome: Diagnostic Utility of Immunohistochemical Staining"*
**作者**: Garcia et al.
**摘要**: 研究探讨了CDKN1C抗体在Beckwith-Wiedemann综合征(BWS)诊断中的应用，通过免疫组化分析发现胎盘和胚胎组织中CDKN1C蛋白表达缺失与BWS相关，验证了该抗体的临床诊断价值。
2. **文献名称**: *"Epigenetic Regulation of CDKN1C in Human Cancers: A Comparative Study Using Western Blot and qRT-PCR"*
**作者**: Tanaka et al.
**摘要**: 利用CDKN1C特异性抗体进行Western blot和免疫荧光实验，揭示了癌症组织中CDKN1C表达受启动子甲基化调控，其低表达与肿瘤侵袭性增强相关。
3. **文献名称**: *"Development and Validation of a Monoclonal Antibody for CDKN1C in Murine Models"*
**作者**: Müller et al.
**摘要**: 报道了一种新型CDKN1C单克隆抗体的开发，通过流式细胞术和免疫沉淀验证其在小鼠模型中的特异性，为研究CDKN1C在发育中的作用提供了可靠工具。
4. **文献名称**: *"CDKN1C Expression in Placental Diseases: Correlation with Clinical Outcomes"*
**作者**: Chen et al.
**摘要**: 采用CDKN1C抗体对胎盘组织进行免疫组化分析，发现其表达异常与子痫前期和胎儿生长受限显著相关，提示其作为生物标志物的潜力。
(注：实际文献需通过PubMed、Google Scholar等平台检索确认。)
CDKN1C antibody is a research tool designed to detect and study the cyclin-dependent kinase inhibitor 1C (CDKN1C), also known as p57^KIP2. This protein, encoded by the *CDKN1C* gene located on chromosome 11p15.5. plays a critical role in regulating cell cycle progression by inhibiting cyclin-dependent kinase complexes, thereby preventing G1-to-S phase transition. CDKN1C is particularly important during embryonic development, where it controls cell proliferation, differentiation, and apoptosis. It is maternally expressed due to genomic imprinting, a process in which only the allele inherited from one parent is active.
Mutations or epigenetic dysregulation of *CDKN1C* are linked to developmental disorders such as Beckwith-Wiedemann syndrome (BWS), characterized by overgrowth and cancer predisposition, and Russell-Silver syndrome (RSS), associated with growth retardation. Aberrant CDKN1C expression is also observed in various cancers, including Wilms tumor and adrenocortical carcinoma, where its loss or silencing may contribute to uncontrolled cell proliferation.
CDKN1C antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression, localization, and function in both normal and pathological tissues. These antibodies aid in understanding CDKN1C's role in development, disease mechanisms, and potential therapeutic targeting. Validation of specificity and cross-reactivity is essential due to structural similarities with other CDK inhibitors like p21 and p27.
×
